Doplňkové cílené řízení teploty při akutní těžké otravě oxidem uhelnatým
Cílené řízení teploty v kombinaci s hyperbarickou kyslíkovou terapií při akutní těžké otravě oxidem uhelnatým: multicentrická randomizovaná kontrolovaná klinická studie (zkouška TTM-COHB)
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.
Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Jižní Korea, 26426
- Wonju Severance Christian Hospital
-
-
Incheon
-
Incheon, Incheon, Jižní Korea, 22332
- Inha University Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- ≥ 19 years.
- Patients who received HBO within 24 hours for acute CO poisoning.
- Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
- Signed informed consent prior to study entry.
Exclusion Criteria:
- Cardiac arrest before HBO
- Previous neurocognitive disorders
- Life-threatening underlying disease (ex: advanced cancer)
- Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
- Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
- No admission
- The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
- Pregnancy
- Burns
- More than moderate burn or Inhalation burn
- Burns complicated by other trauma
- Electrical burn
- Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Hypothermia group
Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
|
Aktivní komparátor: Normothermia group
For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Main neurocognitive outcome
Časové okno: At 6 months after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 6 months after CO poisoning
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Neurocognitive outcome
Časové okno: At 1 month after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 1 month after CO poisoning
|
|
Cerebral Performance Category
Časové okno: At 1 month and 6 months after CO poisoning
|
Cerebral Performance Category [range 1 - 5 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
modified Rankin scale
Časové okno: At 1 month and 6 months after CO poisoning
|
modified Rankin scale [range 0 - 6 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
Glasgow outcome scale
Časové okno: At 1 month and 6 months after CO poisoning
|
Glasgow outcome scale [range 1 (worst score) - 5] |
At 1 month and 6 months after CO poisoning
|
|
mini-mental status exam
Časové okno: At 1 month and 6 months after CO poisoning
|
mini-mental status exam |
At 1 month and 6 months after CO poisoning
|
|
Korean version of the Modified Barthel Index
Časové okno: At 1 month and 6 months after CO poisoning
|
Korean version of the Modified Barthel Index |
At 1 month and 6 months after CO poisoning
|
|
Mortality in intensive care unit
Časové okno: Through study completion, an average of 6 months
|
Number of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
Mortality in intensive care unit
Časové okno: Through study completion, an average of 6 months
|
Rate of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Časové okno: Through study completion, an average of 6 months
|
Number of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Časové okno: Through study completion, an average of 6 months
|
Rate of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
Mortality
Časové okno: At 1, 3, and 6 months after CO poisoning
|
Number of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Mortality
Časové okno: At 1, 3, and 6 months after CO poisoning
|
Rate of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Length of stay in intensive care unit and hospital
Časové okno: Through study completion, an average of 6 months
|
Length of stay in intensive care unit and hospital |
Through study completion, an average of 6 months
|
|
Pneumonia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Pneumonia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Časové okno: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
S100ß (serum)
Časové okno: Within 14 days after CO exposure
|
Concentration of S100ß (serum) |
Within 14 days after CO exposure
|
|
Neuronal specific enolase (serum)
Časové okno: Within 14 days after CO exposure
|
Concentration of neuronal specific enolase (serum) |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Časové okno: Within 14 days after CO exposure
|
Number of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Časové okno: Within 14 days after CO exposure
|
Rate of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Yong Sung Cha, MD, Wonju Severance Christian Hospital
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- TTM-COHB trial
- CR220011 (Jiný identifikátor: Wonju Severance Christian Hospital)
- 2021-04-043 (Jiný identifikátor: Inha University Hospital)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .